-
First‐line immunotherapy of metastatic renal cell carcinoma: an updated network meta‐analysis including triplet therapy BJU Int. (IF 4.5) Pub Date : 2024-04-25 Takafumi Yanagisawa, Tatsushi Kawada, Kensuke Bekku, Ekaterina Laukhtina, Pawel Rajwa, Markus von Deimling, Marcin Chlosta, Fahad Quhal, Benjamin Pradere, Pierre I. Karakiewicz, Keiichiro Mori, Takahiro Kimura, Shahrokh F. Shariat, Manuela Schmidinger
ObjectiveTo compare the differential efficacy of first‐line immune checkpoint inhibitor (ICI)‐based combined therapies among patients with intermediate‐ and poor‐risk metastatic renal cell carcinoma (mRCC), as recently, the efficacy of triplet therapy comprising nivolumab plus ipilimumab plus cabozantinib has been published.Patients and MethodsThree databases were searched in December 2022 for randomised
-
Surveillance of non‐muscle‐invasive bladder cancer with blue‐light cystoscopy: a meta‐analysis BJU Int. (IF 4.5) Pub Date : 2024-04-25 Reza Sari Motlagh, Alireza Ghoreifi, Takafumi Yanagisawa, Tatsushi Kawada, Sascha Ahyai, Axel S. Merseburger, Mohammad Abufaraj, Michael Abern, Hooman Djaladat, Siamak Daneshmand, Shahrokh F. Shariat
ObjectiveTo compare the value of flexible blue‐light cystoscopy (BLC) vs flexible white‐light cystoscopy (WLC) in the surveillance setting of non‐muscle‐invasive bladder cancer (NMIBC).MethodsAll major databases were searched for articles published before May 2023 according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) statement. The primary outcome was the accuracy
-
Fluorescence‐guided surgery using cetuximab‐800CW in patients with penile carcinoma BJU Int. (IF 4.5) Pub Date : 2024-04-25 Thomas S. Nijboer, Christa A. M. van der Fels, Jaron G. de Wit, Bas Keizers, Henrik K. Huizinga, Floris J. Voskuil, Maarten J. H. Voskamp, Marius C. van den Heuvel, Max J. H. Witjes, Igle Jan de Jong
ObjectiveTo investigate the feasibility of fluorescence molecular imaging (FMI), using cetuximab‐800CW, as an intraoperative tool to determine surgical margins in penile squamous cell carcinoma (PSCC).Patients and methodsA total of 11 patients with PSCC received 75 mg cetuximab followed by 15 mg cetuximab‐800CW 2 days before surgery. FMI of the whole excision specimen and tissue slices was performed
-
Immunotherapy for advanced or metastatic urothelial carcinoma: an abridged Cochrane review BJU Int. (IF 4.5) Pub Date : 2024-04-25 Philipp Maisch, Eu Chang Hwang, Kwangmin Kim, Vikram M. Narayan, Caitlin Bakker, Frank Kunath, Philipp Dahm
ObjectivesTo assess the effects of immunotherapy compared to chemotherapy as first‐ and second‐line treatment of advanced or metastatic urothelial carcinoma.MethodsBased on a published protocol, we performed a systematic search of multiple databases. Two review authors independently performed the literature selection, identified relevant studies, assessed the eligibility of studies for inclusion, and
-
Physiotherapy for continence and muscle function in prostatectomy: a randomised controlled trial BJU Int. (IF 4.5) Pub Date : 2024-04-25 Mifuka Ouchi, Takeya Kitta, Hiroki Chiba, Madoka Higuchi, Yui Abe‐Takahashi, Mio Togo, Naohisa Kusakabe, Sachiyo Murai, Hiroshi Kikuchi, Ryuji Matsumoto, Takahiro Osawa, Takashige Abe, Nobuo Shinohara
ObjectiveTo assess the effectiveness of pre‐ and postoperative supervised pelvic floor muscle training (PFMT) on the recovery of continence and pelvic floor muscle (PFM) function after robot‐assisted laparoscopic radical prostatectomy (RARP).Patients and MethodsWe carried out a single‐blind randomised controlled trial involving 54 male patients scheduled to undergo RARP. The intervention group started
-
Peri‐operative outcomes following radical prostatectomy in the setting of advanced prostate cancer BJU Int. (IF 4.5) Pub Date : 2024-04-24 Rishabh K. Simhal, Kerith R. Wang, Yash B. Shah, Costas D. Lallas, Mihir S. Shah, Thenappan Chandrasekar
ObjectiveTo compare the peri‐operative outcomes of radical prostatectomy (RP) for locally advanced, node‐positive, and metastatic prostate cancer (PCa), as determined through pathological staging, using the American College of Surgeons National Surgical Quality Improvement Project.MethodsWe identified RP procedures performed between 2019 and 2021. Patients were stratified by pathological staging to
-
Robot‐assisted retrograde intrarenal surgery: first clinical experience with the ILY® system BJU Int. (IF 4.5) Pub Date : 2024-04-24 Alba Farré, Oriol Angerri, Andrés Kanashiro, Marta Casadevall, Alessandro Uleri, Josep Balañà, Francisco Sánchez Martin, Félix Millan, Joan Palou, Esteban Emiliani
-
-
Advances in cancer and a new antibiotic to treat complex UTIs BJU Int. (IF 4.5) Pub Date : 2024-04-22
-
-
‘Case of the Month’ from the Department of Urology, Oxford University Hospitals, Oxford, UK: stereotactic radiotherapy to the vas deferens for PSMA‐PET CT detected local recurrence 10 years after radical prostatectomy BJU Int. (IF 4.5) Pub Date : 2024-04-22 Anthony S. Bates, Abhishek D. Sharma, Philip Camilleri, Lisa Browning, Clare Verrill, Freddie C. Hamdy
-
The Getting It right First Time (GIRFT) programme in urology; rationale and methodology BJU Int. (IF 4.5) Pub Date : 2024-04-18 Joseph B. John, William K. Gray, Kieran O'Flynn, Tim W.R. Briggs, John S. McGrath
The Getting It Right First Time (GIRFT) programme is a quality improvement initiative covering the National Health Service in England. The programme aims to standardise clinical practices and improve patient and system level outcomes by utilising data-driven insights and clinically-led recommendations. There are GIRFT workstreams for every medical and surgical specialty, including urology. Defining
-
Intra/inter-observer reliability of cystoscopic sphincter evaluation in men undergoing sling surgery BJU Int. (IF 4.5) Pub Date : 2024-04-16 Manuela Tutolo, Annouschka Laenen, Giuseppe Rosiello, Dirk De Ridder, Luk Bruyneel, Jan Cornelissen, Frank Van der Aa
To assess the intra/inter-observer reliability of cystoscopic sphincter evaluation (CSE) in men undergoing sling surgery for urinary incontinence and if possible to evaluate its correlation with the final clinical decision.
-
Adjuvant intravesical therapy in intermediate-risk non-muscle-invasive bladder cancer BJU Int. (IF 4.5) Pub Date : 2024-04-16 Ekaterina Laukhtina, Paolo Gontero, Marko Babjuk, Marco Moschini, Jeremy Yuen-Chun Teoh, Morgan Rouprêt, Quoc-Dien Trinh, Piotr Chlosta, Péter Nyirády, Mohammad Abufaraj, Francesco Soria, Jakob Klemm, Kensuke Bekku, Akihiro Matsukawa, Shahrokh F. Shariat
To evaluate the impact of adjuvant therapy on oncological outcomes in patients with intermediate-risk non-muscle-invasive bladder cancer (NMIBC), as due to the poorly-defined and overlapping diagnostic criteria optimal decision-making remains challenging in these patients.
-
‘Case of the Month’ from the Department of Urology, Cottolengo Hospital, Torino, Italy: endoscopic combined intrarenal surgery (ECIRS) for a partial staghorn renal stone, one‐step solution using a new percutaneous basket BJU Int. (IF 4.5) Pub Date : 2024-04-16 Cesare M. Scoffone, Cecilia M. Cracco
-
-
Role of diverting colostomy and reconstruction in managing Fournier's gangrene—a narrative review BJU Int. (IF 4.5) Pub Date : 2024-04-16 Siyu Huang, David C. Chen, Marlon Perera, Nathan Lawrentschuk
ObjectiveTo examine the role of bowel diversion and reconstructive surgeries in managing Fournier's gangrene (FG) to facilitate multidisciplinary collaboration between urologists, colorectal and plastic surgery teams.MethodsA review of the literature was conducted using the databases Medline, Embase, PubMed in June 2023. The review included studies that evaluated the outcomes of FG following reconstructive
-
Trimodal therapy vs radical cystectomy in patients with muscle‐invasive bladder cancer: a systematic review and meta‐analysis of comparative studies BJU Int. (IF 4.5) Pub Date : 2024-04-16 Francesco Ditonno, Alessandro Veccia, Francesca Montanaro, Greta Pettenuzzo, Antonio Franco, Celeste Manfredi, Luca Triggiani, Cosimo De Nunzio, Marco De Sio, Mariangela Cerruto, Simone Crivellaro, Alexander Kutikov, Riccardo Autorino, Alessandro Antonelli
ObjectiveTo perform a systematic review and meta‐analysis of trials comparing trimodal therapy (TMT) and radical cystectomy (RC), evaluating differences in terms of oncological outcomes, quality of life, and costs.Materials and MethodsIn July 2023, a literature search of multiple databases was conducted to identify studies analysing patients with cT2‐4 N any M0 muscle‐invasive bladder cancer (MIBC;
-
Use of 18F‐fluoro‐2‐deoxy‐d‐glucose (18F‐FDG) PET/CT for lymph node assessment before radical cystectomy in bladder cancer patients BJU Int. (IF 4.5) Pub Date : 2024-04-16 Mattia Longoni, Pietro Scilipoti, Chiara Re, Giuseppe Rosiello, Luigi Nocera, Francesco Pellegrino, Giuseppe Basile, Mario de Angelis, Leonardo Quarta, Giusy Burgio, Andrea Necchi, Antonio Cigliola, Arturo Chiti, Maria Picchio, Andrea Salonia, Alberto Briganti, Francesco Montorsi, Marco Moschini
ObjectiveTo assess the diagnostic performance of 18F‐fluoro‐2‐deoxy‐d‐glucose (18F‐FDG) positron emission tomograpy (PET)/computed tomography (CT) in nodal staging before radical cystectomy (RC) and pelvic lymph node dissection (PLND) for bladder cancer (BCa).Materials and MethodsThis analysis was based on a cohort of 199 BCa patients undergoing RC and bilateral PLND between 2015 and 2022. Neoadjuvant
-
Population‐based study of disease trajectory after radical treatment for high‐risk prostate cancer BJU Int. (IF 4.5) Pub Date : 2024-04-15 Pär Stattin, Sarah Fleming, Xiwu Lin, Florence Lefresne, Sabine D. Brookman‐May, Suneel D. Mundle, Helen Pai, Dina Gifkins, David Robinson, Johan Styrke, Hans Garmo
ObjectivesTo investigate long‐term disease trajectories among men with high‐risk localized or locally advanced prostate cancer (HRLPC) treated with radical radiotherapy (RT) or radical prostatectomy (RP).Material and MethodsMen diagnosed with HRLPC in 2006–2020, who received primary RT or RP, were identified from the Prostate Cancer data Base Sweden (PCBaSe) 5.0. Follow‐up ended on 30 June 2021. Treatment
-
The FocAL therapy CONsensus (FALCON): enhancing partial gland ablation for localised prostate cancer BJU Int. (IF 4.5) Pub Date : 2024-04-13 Lara Rodríguez‐Sánchez, Robert Reiter, Alejandro Rodríguez, Mark Emberton, Theo de Reijke, Eva M. Compérat, Alberto Bossi, Rafael Sanchez‐Salas
-
Systematic review and network meta‐analysis of re‐intervention rates of new surgical interventions for benign prostatic hyperplasia BJU Int. (IF 4.5) Pub Date : 2024-04-11 Brian Ng Hung Shin, Liang Qu, Handoo Rhee, Eric Chung
ObjectiveTo assess the re‐intervention rates of new surgical benign prostatic hyperplasia (BPH) interventions, as the clinical durability of new surgical interventions for BPH is not widely known.MethodsA critical review of new surgical BPH therapies namely ‘UroLift®’, ‘Aquablation’, ‘Rezum’, ‘prostatic artery embolisation (PAE)’ and ‘temporary implantable nitinol device (iTIND)’ was performed on PubMed
-
How to improve penile cancer management by enhanced centralisation – learning from the Dutch example BJU Int. (IF 4.5) Pub Date : 2024-04-09 Matthias May, Anton Kravchuk, Steffen Lebentrau, Sabine Brookman‐May
-
Fully sexual‐sparing robot‐assisted cystectomy: a step‐by‐step surgical technique BJU Int. (IF 4.5) Pub Date : 2024-04-08 Chiara Vaccaro, Karel Dewulf, Konstantin Richter, Nicolas Branger, Stanislas Rybikowski, Thomas Maubon, Jochen Walz, Geraldine Pignot
-
Transdermal oestradiol and exercise in androgen deprivation therapy (ESTRACISE): protocol BJU Int. (IF 4.5) Pub Date : 2024-04-08 Ilkka Jussila, Juha P. Ahtiainen, Eija K. Laakkonen, Aino Siltari, Antti Kaipia, Tiina Jokela, Minta Kärkkäinen, Rob Newton, Truls Raastad, Heini Huhtala, Teemu J. Murtola, Heikki Seikkula
ObjectiveTo report the protocol of a study evaluating the efficacy of transdermal oestradiol (E2) gel in reducing the adverse effects of androgen deprivation therapy (ADT), specifically on sexual function, and to assess the utility of E2 in combination with supervised exercise.Study Design and MethodsThe primary endpoint of this open‐label Phase IIA randomized controlled trial is the efficacy of transdermal
-
Perspectives on technology – prostate cancer: is local anaesthetic transperineal prostate biopsy really better than transrectal biopsy? BJU Int. (IF 4.5) Pub Date : 2024-04-08 Christopher Berridge, Altan Omer, Francisco Lopez, Richard J. Bryant, Alastair D. Lamb
For many years, transrectal ultrasound‐guided (TRUS) prostate biopsies have been performed to establish a histological diagnosis of prostate cancer. This has been the recommended standard of care procedure, but has always carried risks, in particular the risk of post‐procedural sepsis, and the associated antibiotic burden and risk of development of antibiotic resistance. Transperineal (TP) prostate
-
Urethral cancer: a comprehensive review endorsed by the Global Society of Rare Genitourinary Tumours BJU Int. (IF 4.5) Pub Date : 2024-04-08 Herney Andrés García‐Perdomo, Angélica María Dávila‐Raigoza, Ellie Summers, Lucinda Billingham, Andrea Necchi, Gareth Griffiths, Philippe E. Spiess
ObjectiveTo determine the effectiveness and adverse effects of urethrectomy alone or as part of multimodal therapy (MMT).MethodsA comprehensive search was conducted across MEDLINE (OVID), EMBASE, LILACS and the Cochrane Central Register of Controlled Trials (CENTRAL) databases, from their inception to the present date. The study cohort comprised individuals aged 16 years and older diagnosed with urethral
-
Conservative management in high‐grade renal trauma: a systematic review and meta‐analysis BJU Int. (IF 4.5) Pub Date : 2024-04-03 Johannes Cansius Prihadi, Antoninus Hengky, Stevan Kristian Lionardi
ObjectiveTo systematically investigate and analyse the aggregated data from recent studies to provide a quantitative synthesis for a conservative approach to the management of high‐grade kidney trauma, as accumulating evidence supports the favourable outcomes of a conservative approach.MethodsA comprehensive search was performed using databases, including PubMed, EBSCO, ProQuest, Google Scholar, and
-
Endpoint and control group in prostate cancer screening research: public health basics BJU Int. (IF 4.5) Pub Date : 2024-03-30 Takeshi Takahashi
-
Response to ‘Endpoint and control group in prostate cancer screening research: public health basics’ BJU Int. (IF 4.5) Pub Date : 2024-03-30 Peter C. Albertsen
-
The utility of Martius fat pad in the repair of urogenital fistulae: review of current evidence BJU Int. (IF 4.5) Pub Date : 2024-03-28 Konstantinos Kapriniotis, Ioannis Loufopoulos, Helena C.M. Gresty, Tamsin J. Greenwell, Jeremy L. Ockrim
ObjectiveTo present the contemporary evidence on transvaginal urogenital fistulae (UGF) repair with Martius fat pad (MFP), compared to direct graftless fistula repair.MethodsWe reviewed all available studies reporting lower UGF repair via the transvaginal approach in MEDLINE, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL). The primary outcome of interest was the fistula closure
-
Interaction of patient age and high‐grade prostate cancer on targeted biopsies of MRI suspicious lesions BJU Int. (IF 4.5) Pub Date : 2024-03-27 Jamie S. Pak, Richard Huang, William C. Huang, Herbert Lepor, James S. Wysock, Samir S. Taneja
ObjectivesTo evaluate the interaction of patient age and Prostate Imaging‐Reporting and Data System (PI‐RADS) score in determining the grade of prostate cancer (PCa) identified on magnetic resonance imaging (MRI)‐targeted biopsy in older men.Patients and methodsFrom a prospectively accrued Institutional Review Board‐approved comparative study of MRI‐targeted and systematic biopsy between June 2012
-
Correction to “Setting up a multi-disciplinary Klinefelter syndrome clinic – lessons learnt and shared” by S. Rintoul-Hoad et al. BJU Int. (IF 4.5) Pub Date : 2024-03-27
On page 59 of the Abstracts of the Urological Society of Australia and New Zealand Annual Scientific Meeting, 25–28 February 2023, Melbourne, Australia (BJU Int 2023; 131(S1): 4–82), a second affiliation for the author Ramzy Elnabarawy was omitted. The following has been added: 3Faculty of Medicine, Cairo University, Cairo, Egypt. We apologize for this error.
-
Effect of detrusor underactivity on surgical outcomes of holmium laser enucleation of the prostate BJU Int. (IF 4.5) Pub Date : 2024-03-23 Hyun Ju Jeong, Hyomyoung Lee, Min Soo Choo, Sung Yong Cho, Seong Jin Jeong, Seung‐June Oh
ObjectiveTo evaluate the effect of detrusor underactivity (DUA) on the postoperative outcomes of holmium laser enucleation of the prostate (HoLEP) in patients with benign prostatic hyperplasia (BPH).Patients and MethodsPatients with BPH who underwent HoLEP between January 2018 and December 2022 were enrolled in this prospective database study. Patients were divided into DUA (bladder contractility index
-
Prevalence of non‐neurogenic male lower urinary tract symptoms after kidney transplantation BJU Int. (IF 4.5) Pub Date : 2024-03-23 Alberto Costa Silva, Teresa Pina‐Vaz, Afonso Morgado, Carlos Martins‐Silva, Tiago Antunes‐Lopes, João Alturas Silva
ObjectiveThis review investigates the prevalence of male non‐neurogenic lower urinary tract symptoms (LUTS) after renal transplant, as kidney transplantation is a transformative intervention for patients with end‐stage renal disease significantly enhancing quality of life that might be diminished by LUTS.MethodsThe Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines were followed
-
Screening and active surveillance in prostate cancer: the dilemma continues BJU Int. (IF 4.5) Pub Date : 2024-03-22 Freddie C. Hamdy, Peter C. Albertsen, Jenny L. Donovan
In this month's issue of the Journal, Takahashi questions the value of PSA screening because studies have failed to show a decline in overall mortality [1]. This is a very high public health standard as lethal prostate cancer is a relatively rare disease. Only 3% of men die from this disease annually in most Western countries, and demonstrating a meaningful decline in overall mortality requires studies
-
Reply to: Letter to the editor regarding the article ‘Prostate cancer outcomes following whole‐gland and focal high‐intensity focused ultrasound’ BJU Int. (IF 4.5) Pub Date : 2024-03-22 Matthew G. Parry, Arunan Sujenthiran, Julie Nossiter, Melanie Morris, Brendan Berry, Arjun Nathan, Ajay Aggarwal, Heather Payne, Jan van der Meulen, Noel W. Clarke
-
How can we reduce morbidity after robot-assisted radical cystectomy with intracorporeal neobladder? A report on postoperative complications by the European Association of Urology Robotic Urology Section Scientific Working Group BJU Int. (IF 4.5) Pub Date : 2024-03-21 Francesco Pellegrino, Alberto Martini, Ugo Giovanni Falagario, Juhana Rautiola, Antonio Russo, Laura S Mertens, Luca Di Gianfrancesco, Carlo Andrea Bravi, Jonathan Vollemaere, Muhammad Abdeen, Marco Moschini, Mikolaj Mendrek, Eirik Kjøbli, Stephan Buse, Carl Wijburg, Alae Touzani, Guillaume Ploussard, Alessandro Antonelli, Laura Schwenk, Jan Ebbing, Nikhil Vasdev, Gabriel Froelicher, Hubert John, Abdullah
Robot-assisted radical cystectomy (RARC) is a technically challenging procedure associated with high overall postoperative morbidity [1, 2]. Relative to other forms of urinary diversion, neobladder reconstruction is associated with a higher complication rate [3]. As low morbidity represents one of the pivotal surgical outcomes, efforts must be focused on minimizing the morbidity rate. To achieve this
-
-
-
-
Active surveillance in all cases of screen‐detected prostate cancer BJU Int. (IF 4.5) Pub Date : 2024-03-20 Takeshi Takahashi
-
Online decision aid for patients with prostate cancer evaluated by 11 290 patients and 91 urologists in Germany BJU Int. (IF 4.5) Pub Date : 2024-03-20 Johannes Huber, Philipp Karschuck, Johanna Valdix, Christian Thomas, Rainer Koch, Andreas Ihrig, Tobias Hölscher, Tanja Krones, Elke Kessler, Sabine Kliesch, Clemens Linné, Paul Enders, Maurice‐Stephan Michel, Christian Wülfing, Christer Groeben
ObjectiveTo evaluate the nationwide online decision aid ‘Entscheidungshilfe Prostatakrebs’ (established in 2016, >11.000 users and 60 new users/week) for patients with non‐metastatic prostate cancer (PCa), from the perspective of patients and urologists.Patients and MethodsTo provide personalised information, the tool collects most of the International Consortium for Health Outcomes Measurement standard
-
‘Spin’ in urology non‐randomised studies comparing therapeutic interventions: a temporal analysis BJU Int. (IF 4.5) Pub Date : 2024-03-20 Jeremy Wu, Samuel S. Haile, Wilson Ho, Laurence Klotz, Morgan Yuan, Jason Y. Lee, Yonah Krakowsky
ObjectiveTo determine the prevalence of ‘spin’ (i.e., reporting practices that distort the interpretation of results by positively reflecting negative findings or downplaying potential harms) strategies and level of spin in urological observational studies and whether the use of spin has changed over time.Materials and MethodsMEDLINE and Embase were searched to identify observational studies comparing
-
Impact of an enhanced recovery protocol in frail patients after intracorporeal urinary diversion BJU Int. (IF 4.5) Pub Date : 2024-03-19 Kenji Zennami, Mamoru Kusaka, Shuhei Tomozawa, Fumi Toda, Kazuki Ito, Akihiro Kawai, Wataru Nakamura, Yoshinari Muto, Masanobu Saruta, Tomonari Motonaga, Kiyoshi Takahara, Makoto Sumitomo, Ryoichi Shiroki
ObjectiveTo determine whether an enhanced recovery after surgery (ERAS) protocol enhances bowel recovery and reduces postoperative ileus (POI) in both non‐frail and frail patients after robot‐assisted radical cystectomy with intracorporeal urinary diversion (iRARC).Patients and MethodsThis retrospective cohort study included 186 patients (104 with and 82 without ERAS) who underwent iRARC between 2012
-
Trimodal therapy effect on survival in urothelial vs non‐urothelial bladder cancer BJU Int. (IF 4.5) Pub Date : 2024-03-18 Mario de Angelis, Andrea Baudo, Carolin Siech, Letizia Maria Ippolita Jannello, Francesco Di Bello, Jordan A. Goyal, Zhe Tian, Nicola Longo, Ottavio de Cobelli, Felix K. H. Chun, Fred Saad, Shahrokh F. Shariat, Luca Carmignani, Giorgio Gandaglia, Marco Moschini, Francesco Montorsi, Alberto Briganti, Pierre I. Karakiewicz
ObjectiveTo address cancer‐specific mortality free‐survival (CSM‐FS) differences in patients with urothelial carcinoma of the urinary bladder (UCUB) vs non‐UCUB who underwent trimodal therapy (TMT), according to organ confined (OC: T2N0M0) vs non‐organ confined (NOC: T3–4NanyM0 or TanyN1–3M0) clinical stages.Patients and MethodsWithin the Surveillance, Epidemiology, and End Results database (2004–2020)
-
Cost‐effectiveness analysis of different treatment modalities in BCG‐unresponsive NMIBC BJU Int. (IF 4.5) Pub Date : 2024-03-16 Constantin Rieger, Jörg Schlüchtermann, Enno Storz, Lucas Kastner, David Pfister, Axel Heidenreich
ObjectiveRadical cystectomy (RC) is the standard of care (SOC) in BCG‐unresponsive NMIBC and is associated with a significant health‐related quality‐of‐life burden. Recently, promising results have been published on Gemcitabine/Docetaxel, Pembrolizumab, and Hyperthermic Intravesical Chemotherapy (HIVEC) as salvage therapy options trying to increase the rate of bladder preservation. Here, we performed
-
The optimal number of induction chemotherapy cycles in clinically lymph node-positive bladder cancer BJU Int. (IF 4.5) Pub Date : 2024-03-12 Markus von Deimling, Laura S. Mertens, Marc Furrer, Roger Li, Guus A.H. Tendijck, Jacob Taylor, Felice Crocetto, Moritz Maas, Andrea Mari, Renate Pichler, Marco Moschini, Karl H. Tully, David D'Andrea, Ekaterina Laukhtina, Francesco Del Giudice, Gautier Marcq, Maud Velev, Andrea Gallioli, Simone Albisinni, Keiichiro Mori, Abhinav Khanna, Michael Rink, Margit Fisch, Andrea Minervini, Peter C. Black
To investigate the optimal number of induction chemotherapy cycles needed to achieve a pathological response in patients with clinically lymph node-positive (cN+) bladder cancer (BCa) who received three or four cycles of induction chemotherapy followed by consolidative radical cystectomy (RC) with pelvic lymph node dissection.
-
Is analgesic efficacy of rectus sheath catheter actually non‐inferior to thoracic epidural catheter? BJU Int. (IF 4.5) Pub Date : 2024-03-14 Cheng‐Wen Li, Fu‐Shan Xue, Yi Cheng
-
Long‐term functional outcomes after robot‐assisted radical cystectomy with intracorporeal ileal orthotopic neobladder BJU Int. (IF 4.5) Pub Date : 2024-03-14 Francesco Pellegrino, Pietro Scilipoti, Giuseppe Rosiello, Mattia Longoni, Riccardo Leni, Giuseppe Basile, Leonardo Quarta, Paolo Zaurito, Chiara Re, Mario de Angelis, Francesco Cattafi, Giusy Burgio, Giorgio Gandaglia, Francesco Montorsi, Alberto Briganti, Marco Moschini
-
Re: Impact of lymphovascular invasion on survival in surgically treated upper tract urothelial carcinoma: a nationwide analysis BJU Int. (IF 4.5) Pub Date : 2024-03-14 Fumihiko Urabe
-
Addition of neoadjuvant chemotherapy to a ‘quadrifecta’ composite in radical cystectomy BJU Int. (IF 4.5) Pub Date : 2024-03-14 David D’Andrea, Francesco Soria, Marco Moschini, Ekaterina Laukhtina, Rodolfo Hurle, Stefano Mancon, Alessandro Antonelli, Jeremy Yuen‐Chun Teoh, Shahrokh F. Shariat, Benjamin Pradere
ObjectivesTo evaluate the impact of incorporating neoadjuvant chemotherapy (NAC) into the ‘quadrifecta’ outcomes composite for reporting outcomes of radical cystectomy (RC) creating a pentafecta score.Patients and MethodsThis is a retrospective multicentre analysis of patients treated with RC, with or without NAC, for bladder cancer between 2002 and 2023. The primary outcome was the effect of adding
-
Robot‐assisted single‐port transvesical enucleation of the prostate: step‐by‐step technique and early single‐centre experience BJU Int. (IF 4.5) Pub Date : 2024-03-14 Antonio Franco, Francesco Ditonno, Celeste Manfredi, Leslie Claire Licari, Eugenio Bologna, Edward E. Cherullo, Alexander K. Chow, Srinivas Vourganti, Riccardo Autorino
Introduction In recent years, robot-assisted simple prostatectomy (RASP) has become one of the various minimally invasive techniques for the surgical treatment of severe LUTS due to benign prostatic enlargement [1]. It is primarily recommended for patients with large prostate glands (>80–100 mL) as an alternative to currently available and rapidly evolving transurethral enucleation [2, 3]. The concept
-
Focal therapy for prostate cancer – when to refer? BJU Int. (IF 4.5) Pub Date : 2024-03-14 Nadia Rokan, Deepika Reddy, Tim Dudderidge
Focal therapy (FT) for prostate cancer utilising high-intensity focused ultrasound and cryotherapy has been available in the UK under National Institute for Health and Care Excellence (NICE) guidance special arrangements for over a decade (interventional procedures guidance [IPG] 756 and IPG 423, respectively), with irreversible electroporation recently added (IPG 768). Few centres in the UK provide
-
Prostate tumour visualisation with PET: is image fusion with MRI the answer? BJU Int. (IF 4.5) Pub Date : 2024-03-13 Georges Mehawed, Rebecca Murray, Nicholas J. Rukin, Matthew J. Roberts
Prostate-specific membrane antigen positron emission tomography (PSMA PET)/CT plays an important role in prostate cancer due to superior accuracy for staging than conventional imaging (CT, bone scan). Intraprostatic PSMA PET/CT activity has additive benefit for detection of significant tumour foci [1] and prognostic properties [2]. Although combined PSMA PET/CT and MRI improve sensitivity due to enhanced
-
Protocol of a randomised, controlled trial comparing immediate curative therapy with conservative treatment in men aged ≥75 years with non-metastatic high-risk prostate cancer (SPCG 19/GRand-P) BJU Int. (IF 4.5) Pub Date : 2024-03-12 Sven Löffeler, Helena Bertilsson, Christoph Müller, Kirsti Aas, Hege Sagstuen Haugnes, Bjørg Aksnessæther, Maiju Pesonen, Kristian Thon, Torgrim Tandstad, Teemu Murtola, Mads Hvid Poulsen, Tobias Nordstrøm, Maria Nyre Vigmostad, Fredrik Ottosson, Karin Holmsten, Ola Christiansen, Marit Slaaen, Erik Skaaheim Haug, Anne Holck Storås, Lars Asphaug, Antti Rannikko, Klaus Brasso
Older men (aged ≥75 years) with high risk, non-metastatic prostate cancer (PCa) are increasingly treated with curative therapy (surgery or radiotherapy). However, it is unclear if curative therapy prolongs life and improves health-related quality of life (HRQoL) in this age group compared to conservative therapy, which has evolved considerably during the last decade.
-
Impact of definitions on continence outcomes in a series of 1000 robot‐assisted radical prostatectomies, time for an internationally agreed definition? BJU Int. (IF 4.5) Pub Date : 2024-03-12 Mahmoud Abuelnaga, Rasha Gendy, Mark Yao, Curtis Phelan, Julie Pain, Wanxin Wang, Jirayr Ajzajian, Timing Liu, Aly Sherif Hassaballa, Ben Challacombe, Sashi Kommu, Ben Eddy
-
Evolution of European prostate cancer screening protocols and summary of ongoing trials BJU Int. (IF 4.5) Pub Date : 2024-03-12 Meike J. van Harten, Monique J. Roobol, Pim J. van Leeuwen, Peter‐Paul M. Willemse, Roderick C.N. van den Bergh
Population‐based organised repeated screening for prostate cancer has been found to reduce disease‐specific mortality, but with substantial overdiagnosis leading to overtreatment. Although only very few countries have implemented a screening programme on a national level, individual prostate‐specific antigen (PSA) testing is common. This opportunistic testing may have little favourable impact, while
-
The SUB‐urothelial DUrvalumab InjEction‐1 (SUBDUE‐1) trial: first‐in‐human trial in patients with bladder cancer BJU Int. (IF 4.5) Pub Date : 2024-03-12 Dickon Hayne, Katherine Ong, Nicole Swarbrick, Steve P. McCombie, Andrew Moe, Cynthia Hawks, Pravin Viswambaram, Ciara Conduit, Elizabeth Liow, Lisa Spalding, Jayne Lim, Thomas Ferguson, Katie Meehan, Ian D. Davis, Andrew D. Redfern
ObjectivesTo assess the safety of sub‐urothelial injection of durvalumab and examine the impact on tissue and circulating immune cell populations.Patients and MethodsThe patients were chemotherapy and immunotherapy naïve (bacille Calmette‐Guérin allowed) with non‐metastatic muscle‐invasive bladder cancer or non‐muscle‐invasive bladder cancer planned for radical cystectomy (RC). The study was a Phase
-
Efficacy and safety of tibial nerve stimulation using a wearable device for overactive bladder BJU Int. (IF 4.5) Pub Date : 2024-03-12 Limin Liao, Xing Li, Tie Chong, Qi Chen, Zhihui Xu, Banggao Huang, Min Chen, Haoran Li, Zhongqing Wei, Yunpeng Shao, Jianxin Lu, Ran Pang, Xunhua Li, Yiming Wang
ObjectiveTo evaluate the efficacy and safety of a wearable, smartphone‐controlled, rechargeable transcutaneous tibial nerve stimulation (TTNS) device in patients with overactive bladder (OAB).Patients and MethodsThis multicentre, prospective, single‐blind, randomised clinical trial included eligible patients with OAB symptoms who were randomly assigned to the stimulation group or sham group. The primary